
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
The first FDA-approved device to measure airway inflammation in asthma patients.
Newly approved airway inflammation hand-held device






